HUMA Humacyte Inc

P/E --
Forward P/E 35.84
Price/Sales 97.34
Beta 2.457
Div Yield --
Market Cap --

Company Analysis

Latest News

🟒 Humacyte is trading 5.8% up in after-hours trading

Humacyte is trading 5.82% up at $0.37 after the October 14 regular-session close of $0.35; no clear company-specific after-hours catalyst was identified. -...

🟒 Humacyte is trading 5.3% up; no clear catalyst identified

Humacyte is trading 5.27% up at $0.38 on October 14, 2026, with no clear company-specific catalyst identified. - The Phase 3 V012 presentation announcement...

🟒 Humacyte is trading 5.88% up in pre-market on October 14, 2026 with no clear catalyst

Humacyte is trading at $0.38, up 5.88% in pre-market, with no clear company-specific catalyst identified. - Pre-market volume was not provided. - Humacyte...

πŸ”΄ Humacyte is trading 6.3% down with no clear catalyst

Humacyte is trading 6.3% lower at $0.37 on October 13, 2026; no specific catalyst for the decline has been identified. - Major U.S. indices are nearly flat,...

πŸ”΄ Humacyte is trading 11% down with no clear catalyst identified

Humacyte is trading 10.51% down at $0.40, with no clear company-specific announcement identified for the October 9 move. - The decline extends a 5.34% drop on...

πŸ”΄ Humacyte is trading 6% down as recent decline continues

Humacyte is trading at $0.42 (-6.13%), with no identified company-specific catalyst for the October 9 decline. - Shares also fell 5.34% on October 8,...

🟒 Humacyte is trading 10% up in pre-market; rebound catalyst remains unclear

Humacyte is trading at $0.49, up 9.84%, in pre-market on October 9, 2026; no fresh company-specific announcement explaining the move was identified. - The...

πŸ”΄ Humacyte is trading 5.55% down on October 8, 2026 amid biotech-sector weakness; direct cause remains unclear

Humacyte is trading at $0.45, down 5.55% on October 8; no clear company-specific announcement explaining the decline was identified. - Barclays maintained a...

🟒 Humacyte is trading 5.8% up in pre-market

Humacyte is trading 5.8% up at $0.51 in pre-market on October 7, 2026, versus its October 6 close of $0.48; no clear company-specific announcement explaining...

πŸ”΄ Humacyte is trading 6% down with no clear catalyst identified

Humacyte is trading at $0.49, down 6.02%, with no clear company-specific catalyst identified for the October 5 decline. - Humacyte’s latest listed press...

🟒 Humacyte is trading 5.6% up today amid a broad market rally

Humacyte is trading at $0.53, up 5.61%, alongside a broad market rally. - The S&P 500, Nasdaq and Dow were all higher, with the Nasdaq gaining the most. -...

Humacyte Investor State Street Sells 2.2 Million Shares, Cuts Stake 72.3%

Humacyte Investor State Street Sells 2.2 Million Shares, Cuts Stake 72.3%

State Street Corp. sold 2,201,392 shares of Humacyte, Inc., reducing its stake by 72.3%. It now owns 842,537 shares, or 0.30% of the company, valued at...

🟒 Humacyte is trading 6.8% up in pre-market β€” no clear company-specific catalyst identified

Humacyte is trading 6.8% up at $0.59 before the September 28, 2026 session; no clear company-specific catalyst was identified. - The latest notable company...

🟒 Humacyte is trading 5.49% up today in pre-market with no clear catalyst

Humacyte is trading at $0.60, up 5.49%, with no clear company-specific catalyst identified for September 25, 2026. β€’ Recent company releases concern an...

🟒 Humacyte is trading 5% up in pre-market as broader growth-stock demand lifted risk appetite

Humacyte is trading 5.09% up at $0.60 after broader growth-stock demand and firmer U.S. futures supported pre-market risk appetite on September 17, 2026. -...

🟒 Humacyte is trading 6% up today amid possible growth-stock demand and pre-Fed positioning

Humacyte is trading 6% up at $0.58, and broader growth-stock demand and pre-Fed positioning may be supporting shares. - Broader biotech sector is down...

🟒 Humacyte is trading 5% up today amid a sector-driven biotech rebound

Humacyte is trading at $0.60 (+5.15%) as biotech trading rebounds after recent weakness. - It is rebounding on September 2, 2026, after closing at $0.57...

πŸ”΄ Humacyte is trading 5% down today amid broad biotech weakness

Humacyte is trading 5% down at $0.57 amid broader biotech weakness; no confirmed company-specific announcement was identified for September 1, 2026. - XBI is...

πŸ”΄ Humacyte is trading 5.69% down today with no confirmed catalyst

Humacyte is trading at $0.61, down 5.69%, with no confirmed catalyst identified for today’s decline. - No fresh August 31, 2026 company-specific announcement...

πŸ”΄ Humacyte falls 5.6% β€” Biotech Sector Declines Amid Fed Rate Hike Fears

With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...